Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium voltage-gated channel subfamily A regulatory beta subunit 2 (KCNAB2)
- Target
- KCNAB2
- Molecular classification
- Ion channel auxiliary subunit, Voltage-gated potassium channel beta subunit, Aldo-keto reductase family
01
Overview
Potassium voltage-gated channel subfamily A regulatory beta subunit 2 (KCNAB2) encodes Kvβ2, an auxiliary cytoplasmic subunit that associates with voltage-gated potassium (Kv) channel alpha subunits, particularly of the KCNA (Kv1/Shaker) family. Kvβ2 regulates channel gating kinetics, increases surface expression of Kv1 channels, and promotes inactivation and closure of channel complexes, helping to prevent neuronal hyperexcitability. KCNAB2 is part of both the ion channel and aldo-keto reductase families, reflecting enzymatic activity as well as its key role in ion channel modulation. Alterations in KCNAB2 expression or function are implicated in various diseases, including epilepsy, cardiac arrhythmias, lung cancer, and syndromes involving cognitive deficits or developmental delays. No specific drugs currently target this subunit directly, but modulation of the Kv channel complex involving KCNAB2 is relevant to various physiological and disease states.
- Other names
- Voltage-gated potassium channel subunit beta-2Kv-beta-2KCNA2BKCNK2hKvbeta2AKR6A5HKvbeta2HKvbeta2.1HKvbeta2.2Potassium channel, voltage-gated, shaker-related subfamily, beta member 2
02
Mechanism of action
Modulation of Kv channel inactivation/trafficking (indirect effect in complexes containing Kvα subunits); Enhancement or reduction of potassium current via auxiliary subunit function
03
Biological functions
Regulation of potassium channel gating kineticsRegulation of channel trafficking and surface expressionModulation of neuronal excitabilityRegulation of neurotransmitter releaseRegulation of heart rateRegulation of insulin secretionSmooth muscle contractionEpithelial electrolyte transportCell volume regulation
04
Disease associations
EpilepsyChromosome 1p36 deletion syndromeCancer (notably non-small-cell lung cancer)Cardiovascular disease (e.g., atrial fibrillation)Neurodevelopmental and cognitive disorders
05
Safety considerations
Altered KCNAB2 expression or function can lead to neuronal and cardiac hyperexcitabilityPotential pro-arrhythmic or epileptogenic risk if targeted by drugs nonselectively
06
Interacting drugs
No drugs directly targeting KCNAB2 are currently approved or reported in standard pharmacological databases. Some potassium channel blockers or modulators affect the overall Kv channel complex but not specifically the beta-2 subunit.
07
Biomarkers
KCNAB2 expression may serve as a biomarker in non-small-cell lung cancer prognosis and as a candidate gene in 1p36 deletion syndrome.
Beyond the preview
Go deeper on Potassium voltage-gated channel subfamily A regulatory beta subunit 2 (KCNAB2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Potassium voltage-gated channel subfamily A regulatory beta subunit 2 (KCNAB2).